Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 374.86 |
Low | 374.86 |
Bid | -- |
Offer | -- |
Previous close | 374.86 |
Average volume | -- |
---|---|
Shares outstanding | 1.38bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 168.93bn HKD |
EPS (TTM) | -4.93 HKD |
Data delayed at least 20 minutes, as of Jul 16 2024.
More ▼
Press releases
- BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
- BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
- BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
- BeiGene to Present at the Jefferies London Healthcare Conference
- BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
- BeiGene Mourns Death of Beloved Board Member Donald Glazer
- BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
- BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
- Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
More ▼